Eli Lilly CDR (CAD Hedged)

Vanda Pharmaceuticals reported positive Phase 2 results showing tradipitant, an oral NK-1 receptor antagonist, reduced vomiting by 50% in patients receiving GLP-1 therapy for obesity.

Nxera Pharma announced a focused restructuring plan targeting ≥JPY50 billion in net sales and ≥30% operating profit margin by 2030, with a 15% global workforce reduction affecting approximately 60 jobs.

Mangoceuticals has launched MangoRx Direct and PeachesRx Direct programs providing direct access to FDA-approved GLP-1 medications Zepbound and Wegovy through partnerships with Eli Lilly and Novo Nordisk.

Gate Bioscience closed a $65 million oversubscribed Series B financing led by Forbion, with participation from Eli Lilly and Company and existing investors, bringing total capital raised to $135 million.

Medicxi successfully raised €500 million ($581 million) for its sixth fund, demonstrating strong investor confidence in its asset-centric investment approach.

ABL Bio signed a $2.6 billion technology transfer and joint development agreement with Eli Lilly for its Grabbody double antibody platform, marking one of the largest biotech deals in South Korea's history.

The Centers for Medicare & Medicaid Services announced the GENEROUS Model, a voluntary pilot program launching in 2026 that will allow participating state Medicaid programs to purchase select drugs at prices aligned with those paid in other developed countries.

Foghorn Therapeutics reported continued progress in its Phase 1 dose escalation trial of FHD-909 for SMARCA4-mutated cancers, primarily targeting non-small cell lung cancer patients.

Nobel Laureate David Baker's lab at the University of Washington has successfully used AI to design antibodies from scratch with atomic precision, compressing discovery timelines from years to weeks.

The Health Resources and Services Administration has approved eight pharmaceutical companies to participate in the 340B Rebate Model Pilot Program, which will begin on January 1, 2025.